

1 **Prediction of the risk for diabetic neuropathy among diabetes mellitus patients at**
2 **selected referral hospitals, in Amhara regional state Northwest Ethiopia, January,**
3 **2005- December 2021; Development and validation of risk prediction model**

4 Negalgn Byadgie Gelaw^{*1*} Achenef Asmamaw Muche² Adugnaw Zeleke Alem³ Nebiyu
5 Bekele Gebi⁴ Yazachew Moges Chekol⁵ Tigabu Kidie Tesfie⁶ Tsion Mulat Tebeje⁷

6 ¹Department of public health, Mizan- Aman College of health sciences, Mizan- Aman,
7 Ethiopia

8 ²Department of Epidemiology and biostatistics, College of medicine and health sciences,
9 University of Gondar, Gondar, Ethiopia

10 ³Department of Epidemiology and biostatistics, College of medicine and health sciences,
11 University of Gondar, Gondar, Ethiopia

12 ⁴Department of internal medicine, School of Medicine, University of Gondar comprehensive
13 specialized hospital, Gondar, Ethiopia

14 ⁵Department of Health Information Technology, Mizan Aman College of health sciences,
15 Mizan-Aman, Ethiopia

16 ⁶ Department of Public Health, College of Health Sciences, Debre Markos University, Debre
17 Markos, Ethiopia

18 ⁷ Unit of Epidemiology and biostatistics, School of public health, college of medicine and
19 health sciences, Dilla University, Dilla, Ethiopia

20 Corresponding Author ^{*1*} (negalgnbyadgie21@gmail.com)

21 Emails:

22 NBG; negalgnbyadgie21@gmail.com

23 AAM; ashua2014@gmail.com

24 AZA: aduzeleke2201@gmail.com

25 NBG; dawabekele@gmail.com

26 YMC; yazachewmoges@gmail.com

27 TKT; tigabukidie@gmail.com

28 TMT; yemarina12@gmail.com

29

30 **Abstract**

31 **Background:-**Diabetic neuropathy is the most common complication in both Type-1 and
32 Type-2 DM patients with more than one half of all patients developing nerve dysfunction in
33 their lifetime. Although, risk prediction model was developed for diabetic neuropathy in
34 developed countries, It is not applicable in clinical practice, due to poor data, methodological
35 problems, inappropriately analyzed and reported. To date, no risk prediction model
36 developed for diabetic neuropathy among DM in Ethiopia, Therefore, this study aimed
37 prediction the risk of diabetic neuropathy among DM patients, used for guiding in clinical
38 decision making for clinicians

39

40 **Objective:-** Prediction of the risk for diabetic neuropathy among diabetes mellitus patients,
41 in selected referral hospitals, Amhara regional state, northwest Ethiopia,2022

42 **Methods:-** A retrospective follow up study was conducted with a total of 808 DM patients
43 were enrolled from January 1,2005 to December 30,2021 at two selected referral hospitals in
44 Amhara regional state. Multi-stage sampling techniques were used and the data was collected
45 by checklist from medical records by Kobo collect and exported to STATA version-17 for
46 analysis. Lasso method were used to select predictors and entered to multivariable logistic
47 regression with P-value<0.05 was used for nomogram development. Model performance was
48 assessed by AUC and calibration plot. Internal validation was done through bootstrapping
49 method and decision curve analysis was performed to evaluate net benefit of model

50

51 **Results:-**The incidence proportion of diabetic neuropathy among DM patients was 21.29 %(
52 95% CI; 18.59, 24.25).In multivariable logistic regression glycemic control, other
53 comorbidities, physical activity, hypertension, alcohol drinking, type of treatment , white
54 blood cells and red blood cells count were statistically significant. Nomogram was
55 developed, has discriminating power AUC; 73.2 %(95% CI; 69.0%, 77.3%) and calibration
56 test (P-value = 0.45). It was internally validated by bootstrapping method with discrimination
57 performance 71.7(95% CI; 67.2 %, 75.9%).It had less optimism coefficient (0.015).To make

58 nomogram accessible, mobile based tool were developed. In machine learning, classification
59 and regression tree has discriminating performance of 70.2 %(95 % CI; 65.8%, 74.6%).The
60 model had high net benefit at different threshold probabilities in both nomogram and
61 classification and regression tree.

62

63 **Conclusion:-** The developed nomogram and decision tree, has good level of accuracy and
64 well calibration, easily individualized prediction of diabetic neuropathy. Both models had
65 added net benefit in clinical practice and to be clinically applicable mobile based tool were
66 developed.

67 **Key-words:-**Prediction, Diabetes mellitus, Diabetic neuropathy, Ethiopia

68 **Background**

69 Diabetes mellitus is metabolic disorder disease characterized by increasing blood glucose
70 level in the body resulting from either defect insulin secretion, insulin action, or both(1) with
71 around 90% have type 2 DM and 10% have type-1 DM(2).According to IDF, the global
72 prevalence of diabetes mellitus in 20-79 year olds at 2021 was estimated to be 536.6 million
73 people, rising to 783.2 million in 2045(3).

74 Globally, around 3 million deaths annually is due to DM and 49.7% living with diabetes
75 undiagnosed (4).It is one of the most common problem in the world has faced both in
76 developed and developing countries (5). In Africa, by 2019, around 19 million adult
77 populations were estimated to have diabetes and it is expected that by 2045 it will be around
78 47 million and similarly in Ethiopia, an estimated 1,699,400 adults were living with diabetes
79 mellitus(6).

80 The chronic hyperglycemia of diabetes mellitus had long-term damage, dysfunction, and
81 failure of different organs such as nerves, eyes, kidneys(7). Diabetic neuropathy defined as
82 presence of symptoms and signs of peripheral nerve dysfunction in people with diabetes
83 mellitus after exclusion of other causes(8).The mechanism of nerve dysfunctions was through
84 metabolic process by hyperglycemia due to oxidative stress, directly affecting nerve fibers
85 (9). It is the most common complication of both type-1 and type-2 DM with more than one
86 half of all patients developing nerve dysfunction in their lifetime (10).

87 The Burdon of diabetic neuropathy common in industrialized countries ranges from in china,
88 33.1%(11) to 40.3% among patients with type-1 diabetes mellitus and 42.2% with type-2
89 diabetes mellitus in Germany (12). Evidence from previous study documented shows that in
90 Latin American and Caribbean countries, the incidence of diabetic neuropathy was 29.2%
91 (13) and in Sri Lankan 28.8%(14).

92 In Africa, according to a systematic review and meta-analysis done, the overall pooled
93 prevalence of diabetic neuropathy was 46% (15). In south Africa 30.3% (16) ,in Ghana 8.1%
94 (17), in Northern Africa, incidence ranges from 21.9% to 60% (18).

95 In Ethiopia, the prevalence of diabetic neuropathy ranges from 16.63% at university of
96 Gondar comprehensive specialized referral hospital to 52.2% at Bahir-Dar city (19), at Tikur-
97 Anbesa and St. Paul's specialized university hospital was 48.2% with 53.6% in type 2 and
98 33.3% in type 1 diabetes mellitus patients(20).

99 As part of NCD prevention and treatment strategies, diabetic neuropathy and related
100 complications are getting attention at the national and international levels(21).Guidelines are
101 recommending that by multidisciplinary team approach can treating and preventing diabetic

102 neuropathy. WHO and other professional society guideline are also recommended that
103 strengthening of the surveillance & management of diabetic neuropathy was important to
104 reduce the incidence and its consequence(22).

105 Despite different strategies and initiatives implemented to reduce the Burdon of diabetic
106 neuropathy, up to one third of patients with diabetes have neuropathic pain(23) which often
107 leads to sleep disturbance, poor quality of life, depression, and unemployment. Both acute
108 and chronic diabetic neuropathies had occur in DM patients (24) that results diabetic foot
109 disease, including ulceration and non-traumatic amputations that might be due to lack of
110 screening tool that can be used to identify diabetic patients who is at risk of diabetic
111 neuropathy.

112 Although, risk prediction model for diabetic neuropathy among DM patients in developed
113 countries was developed, it is not applicable in clinical practice due to poor data,
114 methodological problems, inappropriately analyzed and poorly reported(25). Delay and lack
115 of detection of the complication was mostly resulted from patients being asymptomatic
116 during the early stage of the disease(26).So that a simple and accurate risk prediction tool to
117 identify those at high risk of patents develop to diabetic neuropathy had great value.

118 Early identification of high risk DM patients using simple screening tool , avoids late
119 diagnosis of diabetic neuropathy that reduces huge economic costs and serious
120 complications (27). Thus, a method used to provide information about their level of risk was
121 needed to take timely intervention measures to prevent occurrence of diabetic neuropathy.

122 Many epidemiological studies on diabetic neuropathy, including cross-sectional studies are
123 carried out around the world to explore the risk factors associated with diabetic neuropathy
124 (12, 28) but level of risk to develop diabetic neuropathy for DM patients was unknown.
125 Hence studies suggest that patient specific model like individual patients risk prediction
126 model is useful to alleviate the problem.

127 Risk prediction models have been used to predict the probability of risk of diseases used in
128 medicine and public health to guide clinical decision-making(29).However, risk prediction
129 model for diabetic neuropathy among DM patients have not been developed in Ethiopia.
130 There was variability in the clinical diagnosis of diabetic neuropathy in different setting
131 (30).Thus, this prediction model considers prognostic factors that have been generally
132 monitored in clinical practice and precisely measured to ensure its feasibility and accuracy
133 for clinical application. Currently an urgent change for improvement of the diagnosis and
134 management of diabetic neuropathy were needed(31).

135 According to a previous risk prediction model conducted to identify DM patients at risk of
136 developing diabetic neuropathy being old age(32), sex(33), educational level (34) were
137 significant predictors with area under ROC curve of 0.957. In another study, age(35),
138 residence (3), BMI (36),educational level (34), poor diabetic control(37), type of DM(38),
139 duration of diabetes mellitus (39), number of hypoglycemic drugs used (40) with AUC 0.859
140 were also determinates of diabetic neuropathy. Hemoglobin level(41), presence of other
141 micro and macro vascular complications(13), hypertension(39), type of DM (33) baseline
142 comorbidities(42), complications such as diabetic nephropathy, diabetic-retinopathy(12),
143 lipid profile(triglyceride, cholesterol)levels (43),fasting blood glucose (44, 45), HbA1c (46),
144 high level of alcohol drinking(13) physical inactive(39), eating fat containing foods(47) were
145 the most common predictors of diabetic neuropathy.

146 Although, different strategies and interventions have been made so far, to reduce the Burdon
147 diabetic neuropathy, Overtime at least 50% of individuals with diabetes develop diabetic
148 neuropathy(48).It is preventable through detected early the high risk patients, by providing
149 timely intervention measures. However, identifying high risk patients for diabetic neuropathy
150 was not performed as expected(26).

151 Until an advanced stage, diabetic neuropathy is asymptomatic but it can be prevented through
152 identifying high risk patients and prompt treatment before their complication. Up to my
153 knowledge there is no risk prediction model for diabetic neuropathy among DM patients in
154 Ethiopia. As a result, this risk prediction models alleviate the problem by developing
155 nomogram and decision tree, estimate disease risk, can guide healthcare providers for disease
156 intervention and arrangement future health care needs by providing treatment.

157 Monitoring biomarkers and other predictors is also very essential to be aware of metabolic
158 abnormality by providing meaningful prognostic information that can help to differentiate
159 patients with regard complication and lead the way to change other intervention. This risk
160 prediction model was developed by applying sound statistical methods and analysis to
161 identify DM patients at which level of risk for the development of diabetic neuropathy (49).

162 Besides, the finding of this study was highly useful as a simple clinical tool to guide
163 clinicians for decision making, aid for specific screening of high-risk patients and for their
164 informed choice of treatment to the patients. Therefore, these studies aimed development and
165 validation of risk prediction model for diabetic neuropathy among diabetes mellitus patients
166 in selected referral hospitals at Amhara regional state, Ethiopia.

167

168 **Methods and materials**

169 **Study design and area**

170 An institution-based retrospective follow up study was conducted among patients diagnosed
171 with diabetes mellitus from January 1, 2005 to December 30, 2021. The study area was
172 selected referral hospitals in northwest part of Amara regional state, which includes
173 University of Gondar Comprehensive specialized and referral hospital, Debre markos
174 comprehensive specialized hospital, Tibebe-Gihon comprehensive specialized referral
175 hospital, Felge-Hiwot comprehensive specialized referral hospital, and Debre tabor
176 comprehensive specialized referral hospital.

177 Using lottery Method, University of Gondar comprehensive specialized referral hospital and
178 Felege-Hiwot comprehensive specialized referral hospital was selected. University of Gondar
179 comprehensive specialized hospital found in Gondar town, far from Addis Abeba, the capital
180 city of Ethiopia 750 km and 200 km from Bahir-dar , the capital city of Amhara regional
181 state. It serves for more than 7 million people in northwest Ethiopia. The hospital serves
182 around 24,862 numbers of people are having chronic follow-up per year, and among this,
183 4760 were DM patients.

184 Felege-Hiwot Referral Hospital is found in Bahir-Dar, which is the capital city of Amhara
185 regional state located at 565 km from Addis Ababa, Northwest Ethiopia. It serves as over 7
186 million people from the surrounding area. Around 21,218 people had a chronic follow-up in
187 this hospital and among these 4200 were DM patients. The study setting was displayed below

188 **Population**

189 The source population was all people diagnosed with diabetes mellitus having a follow up at
190 selected referral hospitals in Amhara regional state, North West Ethiopia and all people
191 having confirmed diabetes mellitus started treatment and follow up at selected referral
192 hospitals in Amhara regional state with in follow up period were study population. A
193 diabetes mellitus patient who was enrolled from January 1, 2005 to December 30, 2021 with
194 minimum of two years follow up, at university of Gondar comprehensive specialized hospital
195 and Felege-Hiwot comprehensive specialized referral hospital were included. Diabetes
196 mellitus patients whose date of initiation was not recorded and incomplete charts, those DM
197 patients develop diabetic neuropathy at beginning, transferred in and gestational diabetes
198 mellitus was excluded

199 Sample size calculation and sampling technique

200 In risk prediction model development sample size was calculated through different
 201 approaches/methods either considering Minimum Mean Absolute Prediction Error (MAPE)
 202 to be minimum and use shrinkage factor to be minimize the issue of over fitted model.

203 Therefore, by applying the expected average error of predicting the outcome when the
 204 developed prediction model is going to be applied to new individuals should be considered,
 205 that is called Mean Absolute Prediction Error (MAPE) should be minimum. Sample size also
 206 can be calculated using the following formula by taking the prevalence according to a
 207 systematic review and meta-analysis study done in Ethiopia , the prevalence of diabetic
 208 neuropathy among diabetes mellitus patients was 22%(50).

$$209 \quad n = \exp\left(\frac{-0.508 + 0.259 \ln(\phi) + 0.504 \ln(p) - \ln(\text{MAPE})}{0.544}\right)$$

210Equation 1

211 Here ϕ -is the proportion of diabetic neuropathy P- is the number of predictors used to
 212 predict the diabetic neuropathy and MAPE is the mean absolute prediction error of maximum
 213 5% considered in our case.

$$214 \quad n = \exp\left(\frac{-0.508 + 0.259 \ln(0.22) + 0.504 \ln(22) - \ln(0.05)}{0.544}\right) = 475$$

215 The second method is taking the issue of over fitted model in to consideration in prediction
 216 model. We have targeted less than 10% over fitted model for predicting diabetic neuropathy
 217 in DM patients. The amount of sample size required to minimize the problem of over fitting
 218 should be identified. We consider the following sample size formula.

$$219 \quad n = \frac{P}{(S - 1) \ln\left(1 - \frac{R_{CS}^2}{S}\right)} \dots\dots\dots \text{Equation 2}$$

$$220 \quad R_{CS}^2 = R_{\text{naegelkerke}}^2 * \max(R_{CS}^2) \dots\dots\dots \text{Equation 2a}$$

$$221 \quad \max(R_{CS}^2) = 1 - \exp\left(\frac{2 \ln L_{\text{null}}}{n}\right) \dots\dots\dots \text{Equation 2b}$$

$$222 \quad \ln L_{\text{null}} = E \ln\left(\frac{E}{n}\right) + (n - E) \ln\left(1 - \frac{E}{n}\right) \dots\dots\dots \text{Equation 2c}$$

223

$$224 \quad \ln L_{\text{null}} = 22 \ln\left(\frac{22}{100}\right) + (100 - 22) \ln\left(1 - \frac{22}{100}\right) = -52.7$$

$$225 \quad \max(R_{CS}^2) = 1 - \exp\left(\frac{2 * -52.7}{100}\right) = 0.65$$

$$226 \quad R_{CS}^2 = R_{nagelkerke}^2 * \max(R_{CS}^2) = 0.5 * 0.65 = 0.325$$

$$227 \quad n = \frac{P}{(S-1)\ln\left(1 - \frac{R_{CS}^2}{S}\right)} = \frac{22}{(0.9-1)\ln\left(1 - \frac{0.325}{0.9}\right)} = 492$$

228 Here, $\ln L_{null}$ is the log-likelihood of an intercept-only model; E is the total numbers of DM
229 patients develop diabetic neuropathy, S- shrinkage factor taken as 0.9 for optimum non-over
230 fitted model n- is the arbitrary sample size from it E occurs. Max R_{CS}^2 is the maximum cox-
231 Snell variability explained by the model δ – is the expected model optimism, $R_{nagelkerke}^2$ is
232 also a fundamental overall measure of model fitness, it is usually considered as default of 0.5.

233 From the above different types of approaches for sample size calculation in risk prediction
234 model the largest sample size is 492 and since multi stage sampling technique was used,
235 design effect taken as equal to 1.5, Then $492 * 1.5 = 738$ Finally by adding 15% contingency
236 because of while during data extraction checklist pretesting, to check completeness and
237 clarity of checklist, most of the patient medical record number was absent in the medical
238 record room by taking in to consideration such missing charts, adding 10-15% contingency
239 was recommended so, the total minimum sample size was 849.

240 Multi stage sampling techniques were used by first selecting the referral hospitals in North
241 West part of Amhara regional state. Among these referral hospitals by using lottery method
242 UOG comprehensive specialized referral hospital and Felege-Hiwot comprehensive
243 specialized referral hospital were selected. Then, study participates were selected by first
244 proportion allocation to each selected referral hospitals through the following proportional
245 allocation formula.

$$246 \quad n_i = \frac{n}{N} * N_i \text{ Where } n = \text{Total sample size } N = \text{total population } n_i = \text{sample size for each hospital}$$

247 Finally the study participates was selected by using computer random generated number
248 through preparing sampling frame by arranging his/her medical record number order.

249 A total of 8960 Type-1 and Type-2 diabetes mellitus patients were enrolled from January 1,
250 2005 up to December 30,2021 and had follow up at university of Gondar comprehensive
251 specialized referral hospital and Felege Hiwot comprehensive specialized referral hospital.

252 The flow chart of participates selection was displayed ([Figure-1](#)).

253 **Figure 1:-Flowchart of participant selection for the development of nomogram for**
254 **prediction of diabetic neuropathy among DM patients in selected referral hospitals,**
255 **Amhara regional state, North West Ethiopia, 2005-2021.**

256 **Variables**

257 **Dependent variable**

258 Diabetic neuropathy

259 **Independent variable**

260 **Socio demographic variables:** Baseline age (year), sex, residence, body mass index

261 **Laboratory related variables:** Mean fasting blood glucose level, Mean arterial blood
262 pressure, baseline total cholesterol, baseline triglyceride level, baseline value of WBC, RBC,
263 platelets count, baseline hemoglobin and creatinine level

264 **Diagnosis and treatment related variables;** Type of DM, duration of DM, Type of
265 treatment for DM, hypertension, baseline other comorbidities and adherence

266 **Behavioral related variables;** Alcohol drinking, unhealthy diet, physical activity

267 **Operational definition**

268 **Diabetic neuropathy;** It can be either small fiber neuropathy or large fiber neuropathy.
269 Small fiber neuropathy manifested by pain, tingling, paraesthesia and confirmed by pinprick
270 and temperature examination. Large fiber neuropathy is manifested by numb feet and gait
271 ataxia and confirmed by touch sensation by 10g monofilament, vibration sense by
272 biothesiometer and ankle reflex. A patient is considered as having diabetic neuropathy if
273 he/she is diagnosed as diabetic neuropathy on his/her medical record (51).

274 **Other comorbidities;** if other baseline disease (except hypertension) in DM patients were
275 present such as ischemic heart diseases, stroke, e.t.c

276 **Mean arterial blood pressure;** calculated as $MABP = (SBP + (2 * DBP))/3$

277 ➤ Normal----- 70-100 mmHg

278 ➤ High----- >100mm Hg

279 **Glycemic control:** Patients was classified as per the WHO criteria into:

280 ➤ Good glycemic control = fasting blood glucose of 80–130 mg/dl

281 ➤ Poor glycemic control = fasting blood glucose of > 130 mg/dl----- (52)

282 **Total cholesterol:**

Total Triglyceride

283 ➤ Normal = <200 mg/dl

Normal= <150 mg/dl

284 ➤ High -- >200 mg/dl -----(53)

High----- >150mg/dl -----(53)

285 **White blood cells**

Red blood cells

- 286 ➤ Normal---- 4,500-11,000 cells/micro liter Normal= 4-6 million cells/ml
287 ➤ Low ----- <4,500 cells/ml Low =<4 million cells/ml
288 ➤ High ----- >11,000 cells/ml--(54) High >6 million cells/ml----(54)

289 **Platelets**

Body mass index:

- 290 Normal ----150,000-400,000 cells/ml Underweight = BMI < 18.5 kg/m²
291 Low ----- <150,000 cells/ml Normal weight = BMI 18.5 to 24.9 kg/m²
292 High -- >400,000 cells/ml----- (54) Overweight = BMI >=25 kg/m²-- (55)

293 **Data collection tools and quality control**

294 This risk prediction model was used secondary data source, collected from June 8 to July 10,
295 2022 using the developed data extraction check lists. The reviewed records were identified
296 by their medical registration number. Patient intake form, follow-up card, and DM
297 registration book were used as data sources. Socio-demographic characteristics, behavioral
298 characteristics, baseline, and follow-up clinical and laboratory data were collected from
299 patient cards. The date that patients start regular follow-up treatment until the end of the
300 study to the confirmation of a final event in the study period was collected. Four trained BSc
301 nursing health professional and two public health officer supervisors were recruited for data
302 collection. Training on the objective of the study and how to retrieve records as per data
303 extraction checklists were given to data collectors and supervisors one day before data
304 collection. As well as, random sample from data extracted was crosschecked for its
305 consistency. The information formats were crosschecked with the source card on the spot,
306 and regular supervisions were done.

307 **Data processing and analysis**

308 Data was coded and entered to Kobo collect Version v2022.1.2 for clean-up and then
309 exported to Stata version-17 for analysis. Descriptive statistics (frequency, percentage,
310 proportion, and mean with standard deviation, median with IQR) were used to describe the
311 clinical course of diabetic neuropathy diseases. The candidate prognostic factors were
312 selected by using the least absolute shrinkage and selection operator (LASSO) method, by
313 shrinking variables with very unstable estimates towards zero, it can effectively exclude
314 some irrelevant variables and produce sparse estimations while variables with nonzero

315 regression coefficient was considered as most strongly associated with the response variable.
316 Then selected variables by (LASSO) method were entered in to multivariable logistic
317 regression and model reduction was done using log likelihood ratio test >0.15 and finally p-
318 value < 0.05 in model reduction were taken as statistically significant predictors and beta
319 coefficients with 95% CI was reported. Multicollinearity was checked by variance inflation
320 factor where $VIF > 10$ indicate the presence of multicollinearity.

321 **Missing data management**

322 Missing variable with value $<50\%$, the missing data was handled by multiple imputation
323 through checking the type of missing data. In this risk prediction model the missing variable
324 was checked by fitting statistical test (logistic regression) found a result, the missing variable
325 was associated with the observed variables, indicates that Missing at random (MAR). The
326 percentage of missing value was done by “mdesc” package by STATA version-17 and if the
327 missing value $\geq 50\%$, were not included in our model. From 22 predictors, six of them had
328 complete data: baseline age, sex, residence, type of DM, type of treatment for DM and
329 duration. The remaining missing variables were managed by multiple imputation technique,
330 better that considers mean and variance and decreases uncertainty or bias. The missing
331 variables and its percentage value was found in [\(Supplementary file S-1\)](#)

332 **Risk prediction model development**

333 In risk prediction model development both the prognostic markers and determinates that
334 predict the diabetic neuropathy was selected from socio-demographic factors, diagnosis and
335 treatment related factors, laboratory related factors and behavioral related factors. The
336 determinants factors included in the multivariable logistic regression analysis were selected
337 based on the results of lasso regression method. The theoretical design was the incidence of
338 diabetic neuropathy at a future time “t” is a function of prognostic determinants ascertained
339 at one time (baseline) points before the occurrence of the diabetic neuropathy (“t0”)

340 The occurrence relation was incidence of $DN = f(\text{Comorbidities, glycemic control, alcohol}$
341 $\text{drinking+ physical activity + hypertension+ type of treatment+ WBC count+ RBC count})$

342 Domain: All type-1 and type-2 DM patients at risk for developing diabetic neuropathy

343 **Nomogram and classification and regression tree development**

344 Nomogram, which are reliable prediction tools, with the ability to generate an individual
345 probability of a clinical event by incorporating a number of prognostic determinant variables

346 (56) was developed to predict individual risk of diabetic neuropathy among DM patients at
347 diabetic clinic of university of Gondar comprehensive specialized hospital and Felege Hiwot
348 referral hospital. The total nomogram score were classified as low risk, intermediate and
349 high-risk scores to see size of each category. Classification and Regression Tree (CRT)
350 analysis was performed to determine the complex interactions among the most potent
351 candidate predictors in the final reduced model to build the classification trees. Youden-index
352 was used to estimate cut off point for predictive probability of diabetic neuropathy at
353 different threshold. By choosing the cutoff value get from Youden's index the sensitivity,
354 specificity, NPV, PPV and accuracy was calculated and cut off value was selected depend
355 availability of resources and aim of implemented program.

356 **Risk prediction model performance**

357 The reduced multivariable model was evaluated by calibration and discrimination (57).
358 Model discrimination is the model's ability to discriminate between subjects with and
359 without the diabetic neuropathy was estimated through the areas under the ROC curve. The
360 area under the receiver operating characteristic curve (AUC) ranges between 0.5-1. Model
361 calibration is examined the level of agreement between the diabetic neuropathy probabilities
362 estimated by the model versus the observed diabetic neuropathy frequencies through
363 graphical comparison, calibration plot. Good calibration means that the estimated probability
364 of diabetic neuropathy is similar to the observed diabetic neuropathy frequency. Statistically
365 we checked by the Homer and Lemeshow test with a significant P- value implies that the
366 model is not well calibrated as it performs differently for different risk categories. Finally the
367 results were presented using statement, table , figures and reported according to transparent
368 reporting of multivariable prediction model for individual progress or diagnosis
369 (TRPOID)statement(58)

370 **Internal validation**

371 In risk prediction model, validating the model expected from the researchers in order to apply
372 in clinical practice. In this study by using bootstrapping method internal validation was done
373 to avoid over fitting of the model (57). The first step in bootstrapping method is the model
374 was developed in the full sample. Then multiple random minimum samples (1000) draw
375 from the full sample. The calibration and discrimination of each bootstrap model were
376 compared to the corresponding estimates of the bootstrap models when applied in the

377 original full sample. These differences were averaged, and provide an indication of the
378 average optimism of the bootstrap models.

379 **Decision curve analysis**

380 Decision curve analysis was done to evaluate prediction models that is important for medical
381 decision making to overcome the limitations discrimination and calibration(59). It was done
382 graphically for model, treatment for all, and treatment for none. The net benefit of the
383 developed model for carrying out a certain intervention measure in DM patients at risk of
384 developing diabetic neuropathy was done by decision curve plot.

385 **Mobile based application of Nomogram**

386 Application of the nomogram by mobile based is useful to facilitate limited resources in poor
387 healthcare systems to get evidence based clinical decision making. To make the nomogram
388 accessible to physicians and patients, mobile based application tool were developed for
389 predicting risk of diabetic neuropathy in diabetes mellitus patients. The mobile based tool
390 was developed by “sublime text” application with java script and used to calculate the risk of
391 diabetic neuropathy for DM patients without requiring internet service “off line” in clinical
392 setting. Where clinicians or diabetes mellitus patients enter his/her selected clinical and
393 laboratory data then developed mobile based application toll giving alert as low risk or high
394 risks of diabetic neuropathy to keep or improve their health condition.

395 **Results**

396 **Socio-demographic and behavioral characteristics of DM patients**

397 A total of 808 diabetes mellitus patients who had follow up visit were included. The mean
398 baseline age of diabetes mellitus patients was 45.6 ± 3.1 years. More than three-fourth
399 616(76.2%) diabetes mellitus patients were from urban residents ([Table-1](#))

400 **Table 1:-Socio-demographic and behavioral predictors of diabetic neuropathy among**
401 **diabetes mellitus patients in North West, Ethiopia, 2005-2021 (n=808)**

| Predictors | Diabetic Neuropathy | | Frequency | Percentage |
|------------|---------------------|-----|-----------|------------|
| | Yes | No | | |
| Sex | | | | |
| Male | 73 | 327 | 400 | 49.5 |

| | | | | |
|-------------------|-----|-----|-----|------|
| Female | 99 | 309 | 408 | 50.5 |
| Baseline age | | | | |
| < 45 years | 62 | 321 | 383 | 47.4 |
| >=45 years | 110 | 315 | 425 | 52.6 |
| Residence | | | | |
| Rural | 26 | 166 | 192 | 23.8 |
| Urban | 146 | 470 | 616 | 76.2 |
| Alcohol drinking | | | | |
| Yes | 74 | 98 | 172 | 21.3 |
| No | 287 | 349 | 636 | 78.7 |
| Physical activity | | | | |
| Yes | 311 | 325 | 636 | 78.7 |
| No | 75 | 97 | 172 | 21.3 |
| Unhealthy diet | | | | |
| Yes | 83 | 89 | 172 | 21.3 |
| No | 321 | 315 | 636 | 78.7 |

402

403 **Diagnosis and treatment related characteristics of DM patients**

404 More than two-third of patients 545(67.5%) were type-2 DM patients and half of them
 405 401(49.6%) diabetes mellitus patients were used oral drugs medication. Nearly half of the
 406 diabetes mellitus patients 385(47.6%) had other comorbidities. Majority of diabetes mellitus
 407 patients 557(71.4%) had good adherence ([Table-2](#)).

408 **Table 2:-Clinical predictors of diabetic neuropathy among diabetes mellitus patients**
 409 **North West, Ethiopia, 2005-2021 (n=808)**

| Predictors | Diabetic Neuropathy | | Frequency | Percentage |
|---|---------------------|-----|-----------|------------|
| | Yes | No | | |
| Type of diabetes mellitus | | | | |
| Type-1 DM | 35 | 228 | 263 | 32.5 |
| Type-2 DM | 137 | 408 | 545 | 67.5 |
| Type of treatment for diabetes mellitus | | | | |
| Insulin only | 55 | 293 | 348 | 43.1 |
| Oral drugs only | 96 | 305 | 401 | 49.6 |

| | | | | |
|--------------------------------------|-----|-----|-----|------|
| Insulin and oral drugs | 21 | 38 | 59 | 7.3 |
| Body mass index in kg/m ² | | | | |
| <18.5 | 9 | 28 | 37 | 4.6 |
| 18.5-24.9 | 54 | 191 | 245 | 30.3 |
| >=25 | 109 | 417 | 526 | 65.1 |
| Mean arterial blood pressure | | | | |
| >100 mmHg | 62 | 152 | 214 | 26.5 |
| 70-100 mmHg | 110 | 484 | 594 | 73.5 |
| Other comorbidities | | | | |
| Yes | 50 | 373 | 423 | 52.4 |
| No | 122 | 263 | 385 | 47.6 |
| Adherence | | | | |
| Poor | 52 | 179 | 231 | 28.6 |
| Good | 120 | 457 | 577 | 71.4 |
| Hypertension | | | | |
| Yes | 99 | 244 | 343 | 42.5 |
| No | 73 | 392 | 465 | 57.5 |
| Duration of DM in years | | | | |
| <6 years | 71 | 257 | 328 | 40.6 |
| 6-11 years | 79 | 316 | 395 | 48.9 |
| >11 years | 22 | 63 | 85 | 10.5 |

410

411

412 **Laboratory related characteristics of diabetes mellitus patients**

413 The mean value of fasting blood glucose level was 92 ± 15 and the mean total cholesterol
 414 and total triglyceride level had 189.9 ± 58.7 and 170.5 ± 73.7 mg/dl respectively. (Table-3)

415 **Table 3:-Laboratory related predictors diabetic neuropathy among diabetes mellitus**
 416 **patients North West, Ethiopia, 2005-2021(n=808)**

| Predictor | Mean \pm SD |
|-----------------------------------|------------------|
| Mean fasting blood glucose(mg/dl) | 92 ± 15 |
| Hemoglobin(g/dl) | 13.9 ± 1.8 |
| Total cholesterol level(mg/dl) | 189.9 ± 58.7 |

| | |
|-------------------------------------|--------------------------------------|
| Total triglyceride level(mg/dl) | 170.5 ± 73.7 |
| Creatinine(mg/dl) | 0.9 ± 0.6 |
| White blood cells(Cells/microliter) | 6.9 ± 2.8 x10 ³ cells/mcl |
| Red blood cells(Cells/microliter) | 4.8 ± 0.9x10 ⁶ cells/mcl |
| Platelets(Cells/microliter) | 233 ± 74x10 ³ cells/mcl |

417 **Incidence of diabetic neuropathy**

418 The incidence proportion of diabetic neuropathy was 172 (21.29 %, 95% CI; 18.59, 24.25)
 419 Type-2 diabetes mellitus 137(79.65%) had highest incidence of diabetic neuropathy whereas
 420 35(20.35%) were found in type-1 diabetes mellitus patients. (Figure-2)

421 **Figure 2; Pie chart for the proportion of diabetic neuropathy among diabetes mellitus**
 422 **patients North West, Ethiopia, 2005-2021.**

423 **Prediction model development and validation**

424 **Selected predictors**

425 In this risk prediction model socio-demographic, diagnosis and treatment related, laboratory
 426 and behavioral related predictors were considered for development of prediction model of
 427 diabetic neuropathy.

428 The candidate predictors were selected by least absolute shrinkage and selection operator
 429 (LASSO) regression for the development and validation of model for diabetic neuropathy
 430 (Table-4). Multi- collinearity test was checked by VIF and unhealthy diet was not included in
 431 our model due to high VIF (17.8).

432 **Table 4:- Optimum shrinkage factor (lambda) and potential predictors identified by**
 433 **lasso regression by 10-fold cross validation selection method for diabetic neuropathy**
 434 **among diabetes mellitus patients North west, Ethiopia 2005-2021.(n=808)**

| ID | Description | Lambda | No. of non- zero coefficients | Out of sample dev. Ratio | CV mean deviance |
|------------|------------------------|------------------|-------------------------------|--------------------------|------------------|
| 1 | First lambda | 0.09923 | 0 | 0.0023 | 1.037898 |
| 21 | Lambda before | 0.015437 | 12 | 0.0575 | 0.9759118 |
| *22 | selected lambda | 0.0140656 | 13 | 0.0578 | 0.0756381 |
| 23 | Lambda after | 0.012816 | 13 | 0.0576 | 0.9757846 |
| 27 | Last lambda | 0.0088336 | 19 | 0.0553 | 0.9782416 |

435

436 Thirteen variables were selected by Lasso regression and included in the multiple logistic
 437 regression models (Table-5). Finally, we construct the clinical risk prediction model with
 438 eight statistically significant predictors including hypertension, glycemic control (FBG),
 439 other comorbidities, Alcohol drinking, physical activity, type of treatment for DM, WBC and
 440 RBC count. Goodness of fit test was checked had insignificant p-value 0.3077, best fitted
 441 model.

442 **Table 5:-Multi variable logistic regression for variables retained in the final reduced**
 443 **model to predict diabetic neuropathy among DM patients Northwest Ethiopia, 2005-**
 444 **2021. (n=808)**

| Predictors | Diabetic neuropathy | | Multi variable analysis | | Model reduction |
|------------------------------|---------------------|-----|--------------------------------|---------|-----------------|
| | No | Yes | Beta coefficients (95 % CI) | P-value | P- value |
| Baseline age in years | | | | | |
| <45 years | 321 | 62 | 0 | | |
| >=45 years | 315 | 110 | 0.15(-0.28,0.59) | 0.516 | |
| Sex | | | | | |
| Female | 309 | 99 | 0 | | |
| Male | 327 | 73 | -0.26(-0.63,0.10) | 0.157 | |
| Residence | | | | | |
| Rural | 166 | 26 | 0 | | |
| Urban | 470 | 146 | 0.28(-0.23,0.79) | 0.279 | |
| Type of DM | | | | | |
| Type-1 DM | 228 | 35 | 0 | | |
| Type-2 DM | 408 | 137 | 0.024(-0.6, 0.7) | 0.944 | |
| Mean arterial blood pressure | | | | | |
| 70-100 mmHg | 484 | 110 | 0 | | |
| >100 mmHg | 152 | 62 | 0.15(-0.25,0.56) | 0.459 | |
| Type of treatment | | | | | |
| Both insulin and oral drug | 38 | 21 | 0 | | |
| Insulin only | 305 | 96 | -0.49(-1.32,0.10) | 0.05 | 0.02 * |

| | | | | | |
|------------------------------|-----|-----|---------------------|-------|--------|
| Oral drugs only | 293 | 55 | -0.61(-1.09,0.15) | 0.139 | |
| Baseline glyceimic control | | | | | |
| <130mg/dl | 148 | 25 | 0 | | |
| >=130mg/dl | 488 | 147 | 0.58(-0.01 ,1.16) | 0.04 | 0.04* |
| Other comorbidities | | | | | |
| No | 373 | 50 | 0 | | |
| Yes | 263 | 122 | 1.29(0.85,1.68) | 0.000 | 0.00* |
| Alcohol drinking | | | | | |
| No | 349 | 287 | 0 | | |
| Yes | 98 | 74 | 1.13(.015, 2.25) | 0.04 | 0.003* |
| Physical Activity | | | | | |
| No | 97 | 75 | 0 | | |
| Yes | 325 | 311 | -1.79(-2.94,-0.7) | 0.002 | 0.001* |
| Hypertension | | | | | |
| No | 392 | 73 | 0 | | |
| Yes | 244 | 99 | 0.412 (0.00 , 0.82) | 0.04 | 0.01* |
| White blood cells/microliter | | | | | |
| 4500-11000 | 266 | 82 | | | |
| <4500 | 33 | 20 | -1.14(-2.2, -0.01) | 0.04 | 0.03* |
| >11000 | 337 | 70 | 0.15(-0.58, 0.89) | 0.684 | |
| Red blood cells/microliter | | | | | |
| 4-6 million | 270 | 80 | 0 | | |
| <4 million | 34 | 20 | 0.90(.056 ,1.74) | 0.03 | 0.03* |
| >6 million | 332 | 72 | -0.24(-0.99 0.52) | 0.539 | |
| _cons | | | -1.96(-2.97,0.94) | 0.000 | |

445

446 **Prediction model development using original beta coefficients**

447 By using area under ROC curve the discriminating power of the model was evaluated and
 448 individual predictors in the final reduced model had poor performance discriminating the risk
 449 of diabetic neuropathy among DM patients starting from 51.1 % to 62 .4% but they had good
 450 discriminating ability in combined effect. The predictive performance of model using
 451 combination of other comorbidities, glyceimic control, physical activity and WBC had 70.0%.
 452 The predictive performance powers of each predictor were displayed ([supplementary file S-](#)

453 **2).** The area under curve (AUC) of the final reduced model using original beta coefficients
454 were 73.49 %(95% CI; 69.3%, 77.6%).(Figure-3, A). The developed model had calibration
455 test value (p-value=0.451) well calibrated model, the model well represented the data that
456 was agreement between observed and the predicted probability (Figure-3, B)

457 **Figure 3: The performance of the model using original beta coefficients A) AUC B)**
458 **calibration plot, for prediction of diabetic neuropathy among DM patients North West**
459 **Ethiopia, 2005-2021.**

460 The probability for risk of diabetic neuropathy using original beta coefficients was
461 $P(\text{Diabetic-neuropathy}) = 1 / (1 + \exp(-1.96 + 0.9 * \text{RBC}(\text{low}) - 1.14 * \text{WBC}(\text{low}) + 0.4 * \text{Hypertension}$
462 $(\text{yes}) - 1.79 * \text{Physical activity}(\text{yes}) + 1.13 * \text{Alcohol drinking}(\text{yes}) + 1.29 * \text{other comorbidities}$
463 $(\text{yes}) + 0.58 * \text{Glycemic control}(\text{poor}) - 0.72 * \text{type of treatment}(\text{insulin only}))$

464 **Prediction model development using nomogram**

465 For the sake of simplicity and easy to use in clinical practice the model was developed by
466 nomogram (Logistic regression). All significant regression coefficients in the final reduced
467 model were used for model development. The model presented by nomogram through eight
468 significant variables that predicts diabetic neuropathy was displayed (Figure-4). From
469 nomogram the possible minimum and maximum score was 0 to 47.2 with different threshold
470 probabilities to develop diabetic neuropathy. The cut off value to nomogram score as the
471 probability of 0.24 was 26. Hence, DM patients who had <26 score from nomogram total
472 score was low risk whereas those who had ≥ 26 score from total score was as high risk to
473 develop diabetic neuropathy.

474 **Figure 4:- Nomogram for develop and validate risk prediction model for diabetic**
475 **neuropathy among diabetes mellitus patients, northwest Ethiopia, 2005-2021.**

476 The performance of developed nomogram in predicting diabetic neuropathy was AUC= 73.2
477 %(95% CI; 69.0%, 77.3%), had good level of accuracy (Figure-5, A) and calibration test (p-
478 value 0.502), the model was well calibrated model, indicates the observed probability was
479 agreement with expected probability (Figure-5, B).

480 **Figure 5: Performance of model using nomogram A) AUC B) Calibration plot,**
481 **prediction for the risk of diabetic neuropathy among DM patients North West Ethiopia**
482 **2005-2021.**

483 **Prediction model development using machine learning by classification and**
484 **regression tree**

485 Besides the model developed by nomogram, it also presented by machine learning algorithm
486 with classification and regression tree analysis suitable when continuous and categorical
487 variables used that predict diabetic neuropathy. The prediction rate (accuracy) for diabetic
488 neuropathy in classification and regression tree was 78.7% (Table-6).

489 **Table 6:- Prediction rate of diabetic neuropathy among DM patients using machine**
490 **learning by CRT decision tree in North West Ethiopia, 2005-2021**

491

| Observed | Classification | | |
|--------------------|----------------|------|-----------------|
| | Predicted | | Percent Correct |
| | No | Yes | |
| No | 636 | 0 | 100.0% |
| Yes | 172 | 0 | 0.0% |
| Overall Percentage | 100.0% | 0.0% | 78.7% |

492

493

494 From eight significant variables used for nomogram development, the classification and
495 regression tree (CRT) select five most potent predictors includes other comorbidities, glycemic
496 control, physical activity, White blood cells and red blood cells count. Presence of
497 comorbidities was the most important node that predicts diabetic neuropathy, followed by
498 glycemic control and physical activity; low RBC and high WBC count. For instance, from 172
499 having diabetic neuropathy cases, 59(43.1%) had presence other comorbidities and no doing
500 physical activity were develop diabetic neuropathy. In classification and regression tree there
501 were four depths, six terminal nodes used for decisions (Figure-6).

502 **Figure 6:-Classification and regression decision tree for prediction of diabetic neuropathy**
503 **among diabetes mellitus patients North West Ethiopia 2005-2021**

504 The performance of the classification and regression decision tree was good accuracy with
505 AUC=70.2 %(95 % CI; 65.8%, 74.6%) (Figure:-7, A) and well calibrated model (p-value -
506 0.412) (Figure:-7, B), which means the predicting and observed probability was the same

507 **Figure 7:-The Performance of the model using decision tree A) AUC B) calibration plot**
508 **to prediction of the risk for diabetic neuropathy among DM patients North West**
509 **Ethiopia 2022.**

510 **Internal validation**

511 In order to checking over fitting and bias of the developed model using nomogram and
512 decision tree, bootstrapping technique were used for internal validation. The area under ROC
513 curve was assessed based on the bootstrap dataset coefficients. The developed nomogram
514 was internally validated had AUC; 71.7(95% CI; 67.3 %, 76.0%) (Figure-8, A) and well
515 calibration model (p-value- 0.945)(Figure-8, B)

516 After internal validation the discriminating performance of nomogram was comparable with
517 less optimism coefficients found to be 0.015, which indicates less likely over fitting model
518 and bias. The average calculated value of optimism to the performance model was 0.0075.

519 **Figure 8: The performance of the model using nomogram after bootstrapping A) Area**
520 **under the curve (AUC) B) calibration plot, for the probability of the risk of diabetic**
521 **neuropathy among DM patients North West Ethiopia, 2005-2021.**

522 The performance of the classification and regression decision tree after bootstrapping was the
523 same as the developed CRT decision tree ,good accuracy with AUC=70.2 %(95 % CI;
524 65.8%, 74.6%) (Figure:-9 A) and well calibrated model (p-value:-0.389) (Figure:-9 B). The
525 optimism coefficient was 0.000.

526 **Figure 9:-The performance of the model using classification and regression decision**
527 **tree after bootstrapping A) AUC B) Calibration plot to predict diabetic neuropathy**
528 **among DM patients northwest Ethiopia 2022.**

529 In both nomogram and classification and regression tree (CRT) the discrimination and
530 calibration performance power were comparable, good accuracy so that, they were used to
531 predict the risk of diabetic neuropathy among DM patients (Figure-10)

532 **Figure 10: Comparison of nomogram and decision tree for prediction of diabetic**
533 **neuropathy among DM patients North West Ethiopia 2005-2021.**

534 **Cutoff point for probability of diabetic neuropathy by nomogram and**
535 **CRT**

536 Using the nomogram, optimal cutoff point for predicted probability for risk of diabetic
537 neuropathy by using Youden's index(J) was 0.2447 and the sensitivity, specificity, positive
538 predictive value and negative predictive value was 65.2%(95% CI; 58;0%, 72.2%),

539 71.7%(95% CI; 68.0%, 75.2%), 38.4%(95% CI; 32.7 %, 44.2%), 88.4% (95% CI; (85.3%,
540 91.0%) respectively.(Table-7)

541 **Table 7:-Sensitivity, Specificity, PPV, NPV, LR+, LR- and Accuracy of the nomogram**
542 **at different cut-off points for prediction of diabetic neuropathy among DM patients**
543 **North West Ethiopia 2005-2021.**

| Cutoff | Sensitivity | Specificity | Accuracy | PPV | NPV | LR+ | LR_ |
|------------------|--------------|--------------|--------------|--------------|-------------|------------|------------|
| >=0.1 | 72.1% | 63.5 | 65.4% | 35.3% | 90.4% | 1.9 | 0.4 |
| >=0.2 | 70.4% | 66.4% | 67.2% | 36.1% | 89.2 | 2.1 | 0.4 |
| >=0.24 | 65.2% | 71.7% | 70.3% | 38.4% | 88.4 | 2.3 | 0.4 |
| >=0.3 | 54.7% | 78.6% | 73.5% | 41.0% | 86.5% | 2.5 | 0.5 |
| >=0.4 | 34.3 % | 88.4% | 77.0% | 44.4% | 83.3% | 2.9 | 0.7 |

544

545 In classification and regression tree(CRT) using optimal cutoff point for predicting the
546 probability risk of diabetic neuropathy by using Youden's index was 0.1847 and the
547 sensitivity, specificity, positive predictive value and negative predictive value was 72.09
548 (95% CI; 64.8%, 78.6%), 57.7%(95% CI; 53.8%, 61.6%), 31.5%(95% CI; 27.0 %, 36.4%),
549 88.4% (95% CI; (84.9%, 91.3%) respectively.

550 **Risk classification for diabetic neuropathy using nomogram**

551 For easily practical utility we developed nomogram by using regression coefficients in the
552 final reduced model. The proportion of diabetes mellitus patients to risk of diabetic
553 neuropathy at low risk was 516(63.8%), intermediate risk 282(34.90%) and high risk group
554 10(1.24%). When the risk classified as two categories the proportions of DM patients for risk
555 of diabetic neuropathy at low risk was 516(63.86%) and high risk 292(36.14%).(Table-8)

556 **Table 8: Risk classification for predicting diabetic neuropathy among DM patients**
557 **using nomogram, Northwest Ethiopia, 2005-2021 (n=808)**

| Risk categories' | Total number of DM patients | Incidence of diabetic neuropathy |
|----------------------------|-----------------------------|----------------------------------|
| Low risk(<0.2) | 516(63.86%) | 60(7.4%) |
| Intermediate risk(0.2-0.6) | 282(34.90) | 107(13.3%) |
| High risk(>0.6) | 10(1.24%) | 5 (0.6%) |
| Total | 808(100%) | 172(21.3%) |

558

559 In classification and regression tree (CRT), the proportion diabetes mellitus patients to the
560 risk of diabetic neuropathy at low risk was 150(18.56%), intermediate risk 636(78.72) and
561 high risk 22(2.72%).

562 **Decision Curve analysis**

563 Besides model performance assessed by AUC, calibration plot, sensitivity, specificity and
564 accuracy, clinical and public health utility of the model was also assessed by decision curve
565 analysis. The developed model using nomogram and classification and regression tree (thick
566 red line) had highest net benefit from threshold probabilities greater than 0.1(10%) compared
567 treatments none (thick black line), had high cost benefit ratio. The model has no or similar
568 net benefit to treatment all (thin black line) regardless of their risk across thresholds below
569 0.1 (10%).(Figure-11, A, B)

570

571 **Figure 11:-Decision curve plot A) Nomogram B) Decision tree ,showing the net benefit**
572 **of the developed model for carrying out a certain intervention measure in DM patients**
573 **at risk of diabetic neuropathy Northwest Ethiopia, 2005-2021**

574 **Mobile-based application of nomogram**

575 To make the nomogram accessible to physicians and patients, mobile based application tool
576 were developed for predicting the risk of diabetic neuropathy among diabetes mellitus
577 patients by using “sublime text “application with java script. Where physicians’ or diabetes
578 mellitus patients enter their selected clinical and laboratory data to the developed mobile
579 based tool, then the tool was giving alert as cutoff value 26 get from nomogram, weather they
580 are at low risk (<26) or high risk (>=26) of diabetic neuropathy by calculating cumulating
581 score in order to keep or improve their health condition. In Figure:-15 when we enter data to
582 the tool had score 21.2

583 **Figure 12:-Mobile based application outputs for predicting risk of diabetic neuropathy**
584 **among DM patients Northwest Ethiopia 2005-2021.**

585 **Discussion**

586 This risk prediction model used a multicenter retrospective follow up study to develop a
587 practical tool for prediction of diabetic neuropathy among both type-1 and type-2 DM
588 patients. Our study established a diabetic neuropathy risk prediction model using combined

589 set predictors to be used in the primary care settings, by developing nomogram and decision
590 tree, aid in public health and clinical decision making for clinicians and to patients.

591 There were challenges to diagnose diabetic neuropathy, which needs electro physical and
592 autonomic tests by mono filaments, is not available in low level health care system (60, 61)
593 Hence, predicting the risk of diabetic neuropathy in diabetes mellitus patients using easily
594 measurable predictors were essential to take appropriate measures accordingly.

595 The study finding showed that the incidence proportion of diabetic neuropathy was 21.29
596 %(95%CI; 18.59, 24.25), which is consistent with SRMA study in North Africa, 21.9% (18),
597 Ethiopia, 22% (50), Qatar 23.0%(62) but lower than Tikur Anbesa and St. Paulous
598 hospital, 48.2% (20), SRMA in Africa 46% (15), Srilanka 28.8% (14).

599 These disparities might be number of participants involved with sample size difference, in
600 case small sample size in this study(63), difference way of life style (64) and different level of
601 health care system used for diagnosis. For instance, monofilament examination was not
602 performed in our study area, results asymptomatic patients may not detect.

603 The model was developed by reducing twenty-two candidate predictors to thirteen potential
604 predictors, which were passed to multivariable analysis. The model comprised eight variables
605 identified as independent predictors of diabetic neuropath including glycemic control (FBG),
606 other comorbidities, alcohol drinking, Hypertension, type of treatment for DM, physical
607 activity, WBC and RBC count. This result is supported by previous studies conducted (65),
608 (66), (37), (42), (47), (67).

609 The prediction model developed from eight predictors and nomogram was developed found
610 to have discrimination accuracy of AUC; 73.2% This result showed that a good accuracy
611 discrimination power according to diagnostic accuracy classification criteria(68). The model
612 calibration assessed by calibration plot and Hosmer and Lemeshow test had p-value; 0.502,
613 which had good agreement between observed and expected probability.

614 The predictive role of each predictors was assessed for the identification of individuals at
615 greater risk of diabetic neuropathy and its capacity of score from nomogram for glycemic
616 control (poor), physical activity (no), other comorbidities (yes), alcohol drinking (yes), use
617 combined insulin and oral drugs, hypertension (yes), WBC (high) and RBC (low) was 2.6,
618 10, 7, 6.4, 4, 2.6, 7.8 and 6.8 respectively.

619 The model was internally validated using the bootstrapping method of 1000 repetitions with
620 replacement. The discriminating performance of the model after internal validation had also
621 good discrimination power of AUC ;71.7% with well calibrated model (p value = 0.945).The

622 optimism coefficient was found to be 0.015(1.5%), ensures that the model is less likely over
623 fitting and less sample dependent, can easily and accurately individualized prediction of the
624 risk of diabetic neuropathy.

625 The performance of our model was found to be consistent with other prediction models
626 developed to predict diabetic neuropathy among DM patients, using hypertension, age, heart
627 rate and BMI as predictors, AUC; 71% in china(69) using hypertension, comorbidities,
628 gender, age, obesity, abnormal triglycerides as predictors, AUC; 75% in china (70),but better
629 than a study using glomerular filtration rate, glibenclamide and creatinine as predictors
630 AUC=66.05% in Mexico (71), using age, FBG, PBG, HbA1c, LDL, HDL and BMI as
631 predictors AUC; 55.6% in china(72), using FBG, BMI, age as predictors AUC; 63.50 in
632 Korea (73). This might be due to difference in study participants involved through socio-
633 demographic characteristics , difference number of predictors used in the model development
634 (74).The model calibration based on Hosmer and Lemshow test P-value; 0.945, is consistent
635 another study 0.52 in china (72), indicates well calibrated model.

636 However, the discriminative performance of the model was lower than a study done in Italy
637 using type of DM, smoke, BMI and HbA1c as predictors AUC ; 76.9%(75) and AUC; 85.9%
638 in china(40). This might sample size variation, use variety of validation techniques, the lower
639 number of predictors incorporated in case of our study compared to others, use machine
640 learning algorism, to select the most potent predictors increases the power of the study (74).

641 In our nomogram prediction score, using 0.24 as cutoff point has an acceptable level of the
642 sensitivity; specificity was 65.2%, 71.2%, respectively. Using 0.18 as cut off point in
643 classification and regression tree (CRT) had also acceptable level of sensitivity; specificity
644 was 72.09% and 57.7% respectively. Thus it was better to identify diabetic neuropathy cases
645 and possible to shift the cutoff point to increase either of the accuracy measures depending
646 on the aim of program and availability of resources.

647 The benefit that the developed nomogram and decision tree would add to clinical practice
648 was also presented in the form of a decision curve analysis. In our study the decision curve
649 analysis showed that there was high net benefit than using treat all or treat none strategies
650 when the threshold probability of the patient greater than 0.1(10%) in both nomogram and
651 classification and regression tree(CRT). However, the model is not useful for threshold
652 probabilities below 10%. Thus, threshold probabilities are the most important components of
653 the decision curve analysis depending on which a clinician can decide on whether to use the

654 model or not when there is a need to carry out an intervention for patients at risk of diabetic
655 neuropathy.

656 Although the autonomic tests by monofilament examination and nerve conduction studies
657 gives better diagnosis of diabetic neuropathy(76).However, prediction of diabetic neuropathy
658 among type-1 and type-2 DM patients using clinical and behavioral characteristics of alone
659 enabled to identify low and high risk diabetes mellitus patients.

660 This prediction model is not a replacement of electro physical diagnosis and monofilament
661 examination of diabetes mellitus patients to diagnose diabetic neuropathy (77); however, it
662 will be as screening tool in resource poor settings for further diagnostic workup and
663 management options. Besides the nomogram and decision tree is easier to use in routine
664 clinical and public health practice than regression models and has comparable discrimination
665 and calibration.

666 This study has following strengths. Firstly, it was conducted multicenter study and mobile
667 based application toll was developed for easily applicability. Secondly, the model was
668 internally validated using bootstrapping technique, resulted small optimism coefficient,
669 indicating our model is less likely over fitted model, can easily predict the risk of diabetic
670 neuropathy. Thirdly, this prediction model is constructed from easily obtainable clinical and
671 behavioral predictors that make it applicable in primary care settings. Finally the model was
672 also developed by classification and regression tree analysis to show the interaction effect of
673 each predictor to the risk of diabetic neuropathy.

674 However, the findings from this study should be interpreted with the perspective of the
675 following limitations. Even if multicenter studies, the model did not validate in separate
676 datasets so that it needs external validation before using it in another context. In addition
677 most diabetic neuropathy patient was asymptomatic may missed cases, who had no sign and
678 symptoms. The study had many missing predictors due to retrospective study design.
679 Generally the model will provide its maximum benefit in clinical practice provided that all
680 the required predictor information is collected and developing mobile based application
681 makes it the nomogram easily applicable for clinicians and to patients.

682 **Conclusion and recommendation**

683 The model was developed from precisely measured, clinical and behavioral predictors found
684 in primary health care setting includes glycemic control(FBG), hypertension, physical
685 activity, other comorbidities, alcohol drinking, type of treatment for DM, WBC and RBC

686 count. The model was presented by nomogram and decision tree with having good
687 discriminating performance power and well calibrated. It was internally validated by
688 bootstrapping techniques with small optimum coefficients, less likely of over fitting of the
689 model. The nomogram was better than decision tree, helps us to do a risk stratification of
690 diabetes mellitus patients and to identify those at higher risk of having diabetic neuropathy.
691 Subsequently, high-risk groups can be linked to a center, which is equipped with electro
692 physical diagnosis and monofilament examination centers for further assessment and better
693 management. The nomogram and decision tree had added net benefit in clinical practice as it
694 was assured by decision curve analysis across different threshold probabilities. To make
695 easily accessible and applicable of nomogram for clinicians and to patients, mobile based
696 application tool (off line) were developed, that works for both type-1 and Type-2 DM
697 patients to calculate their risk in order to take appropriate intervention measures timely.
698 Based on study findings, we recommend that for health professionals, who are providing
699 health care services at diabetes mellitus chronic follow up clinic, use the nomogram
700 developed by mobile based application tool to identify high risk of diabetic neuropathy
701 patients for early management and treatment. Additionally Patients use this developed mobile
702 based application tool for their informed choice of treatment by calculating their
703 individualized risk either to keep or improve their health condition. Finally for future
704 researchers improve the model by adding additional predictors like HbA1c, family history of
705 DM and smoking through prospective study design and using monofilament examination by
706 detect enough number of events. Besides, validate externally by using independent sample
707 datasets to be applicable in all health institution.

708 **Abbreviations**

709 AUC; Area under the Curve BMI; Body Mass Index CI; Confidence Interval
710 CRT; Classification and Regression Tree DBP; Diastolic Blood Pressure DCA; Decision
711 Curve Analysis DM; Diabetes Mellitus DPN; Diabetic Peripheral Neuropathy
712 FBG; Fasting Blood Glucose HDL; High Density Lip-Protein HbA1c; Glycated Hemoglobin
713 A1 c ICT; Information Communication Technology IDF; International Diabetes Federation
714 IQR ; Inter Quartile Range LASSO; Least Absolute Shrinkage and Selection Operator LDL;
715 Low Density Lip-Protein LR+; Log Likelihood Ratio Positive LR_ ; Log Likelihood Ratio
716 Negative MNSI ; Michigan Neuropathy Screening Instrument NPV; Negative Predictive
717 Value PBG; Post Bradial Glucose PPV; Positive Predictive Value RBC; Red Blood Cells
718 ROC; Receiver Operating Characteristics SBP; Systolic Blood Pressure SRMA ; Systematic

719 Review and Meta-Analysis T1DM; Type-1 Diabetes Mellitus T2DM;Type-2 Diabetes
720 Mellitus TC; Total Cholesterol TG; Total Triglyceride UOG; University of Gondar WBC;
721 White Blood Cells

722 **Declarations**

723 **Ethics approval and consent to participate**

724 The study use ethical clearance from university of Gondar for the collection of information
725 from subjects ([supplementary file-S3](#))

726 **Availability of data and materials**

727 Data is available on the manuscript and as supplementary files.

728 **Competing Interests**

729 The authors declare that they have no conflict of interest.

730 **Funding**

731 Funding was obtained from Mizan Aman college of health science, Mizan-Aman, Ethiopia
732 (25,000 Ethiopian Birr)

733 **Author's Contributions**

734 **Conceptualization:** Negalgn Byadgie Gelaw, Achenef Asmamaw Muche, Adugnaw Zeleke
735 Alem, Yazachew Moges Chekol, Tigabu Kidie Tesfie, Tsion Mulat Tebeje, Nebiyu Bekele
736 Gebi

737 **Data curation:** Negalgn Byadgie Gelaw, Achenef Asmamaw Muche, Adugnaw Zeleke
738 Alem, Yazachew Moges Chekol, Tigabu Kidie Tesfie ,Tsion Mulat Tebeje, Nebiyu Bekele
739 Gebi

740 **Formal analysis:** Negalgn Byadgie Gelaw, Achenef Asmamaw Muche, Adugnaw Zeleke
741 Alem, Yazachew Moges Chekol, Tigabu Kidie Tesfie, Tsion Mulat Tebeje, Nebiyu Bekele
742 Gebi

743 **Investigation:** Negalgn Byadgie Gelaw, Achenef Asmamaw Muche, Adugnaw Zeleke Alem,
744 Yazachew Moges Chekol, Tigabu Kidie Tesfie, Tsion Mulat Tebeje, Nebiyu Bekele Gebi
745 **Methodology:** Negalgn Byadgie Gelaw, Achenef Asmamaw Muche, Adugnaw Zeleke
746 Alem, Yazachew Moges Chekol, Tigabu Kidie Tesfie, Tsion Mulat Tebeje, Nebiyu Bekele
747 Gebi
748 **Software;** Negalgn Byadgie Gelaw, Achenef Asmamaw Muche, Adugnaw Zeleke Alem,
749 Yazachew Moges Chekol, Tigabu Kidie Tesfie, Tsion Mulat Tebeje, Nebiyu Bekele Gebi
750 **Validation:** Negalgn Byadgie Gelaw, Achenef Asmamaw Muche, Adugnaw Zeleke Alem,
751 Yazachew Moges Chekol, Tigabu Kidie Tesfie, Tsion Mulat Tebeje, Nebiyu Bekele Gebi
752 **Visualization:** Negalgn Byadgie Gelaw, Achenef Asmamaw Muche, Adugnaw Zeleke
753 Alem, Yazachew Moges Chekol, Tigabu Kidie Tesfie, Tsion Mulat Tebeje, Nebiyu Bekele
754 Gebi
755 **Writing original draft:** Negalgn Byadgie Gelaw, Achenef Asmamaw Muche, Adugnaw
756 Zeleke Alem, Yazachew Moges Chekol, Tigabu Kidie Tesfie, Tsion Mulat Tebeje, Nebiyu
757 Bekele Gebi
758 **Writing – review & editing:** Negalgn Byadgie Gelaw, Achenef Asmamaw Muche,
759 Adugnaw Zeleke Alem, Yazachew Moges Chekol, Tigabu Kidie Tesfie, Tsion Mulat Tebeje,
760 Nebiyu Bekele Gebi
761 All authors read and approved the final manuscript.

762 **Acknowledgments**

763 We greatly acknowledge Mizan Aman College of health sciences for sponsorship and
764 university of Gondar

765 **Supplementary file**

766 **S1:- Missing variables and its percentage for prediction of diabetic neuropathy among**
767 **DM patients Northwest Ethiopia, 2005-2021.**
768 **S2: - Predictive performance of for individual and combined predictors by AUC value**
769 **for prediction of diabetic neuropathy among DM patients North West Ethiopia 2005-**
770 **2021.**
771 **S3:-Ethical Clearance letter obtained from university of Gondar**

772

773 **References**

- 774 1. Czech MP. Insulin action and resistance in obesity and type 2 diabetes. *Nature*
775 *medicine*. 2017;23(7):804-14.
- 776 2. Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes
777 mellitus and its complications. *Nature Reviews Endocrinology*. 2018;14(2):88-98.
- 778 3. Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, et al. IDF
779 Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021
780 and projections for 2045. *Diabetes research and clinical practice*. 2022;183:109119.
- 781 4. Cho NH, Shaw JE, Karuranga S, Huang Y, da Rocha Fernandes JD, Ohlrogge AW, et
782 al. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for
783 2045. *Diabetes Res Clin Pract*. 2018;138:271-81.
- 784 5. Tuomi T, Santoro N, Caprio S, Cai M, Weng J, Groop L. The many faces of diabetes:
785 a disease with increasing heterogeneity. *Lancet (London, England)*. 2014;383(9922):1084-
786 94.
- 787 6. Cho N, Shaw J, Karuranga S, Huang Y, da Rocha Fernandes J, Ohlrogge A, et al. IDF
788 Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045.
789 *Diabetes research and clinical practice*. 2018;138:271-81.
- 790 7. Association AD. Standards of medical care in diabetes—2016 abridged for primary
791 care providers. *Clinical diabetes: a publication of the American Diabetes Association*.
792 2016;34(1):3.
- 793 8. Edwards JL, Vincent AM, Cheng HT, Feldman EL. Diabetic neuropathy:
794 mechanisms to management. *Pharmacology & therapeutics*. 2008;120(1):1-34.
- 795 9. Rojas-Carranza CA, Bustos-Cruz RH, Pino-Pinzon CJ, Ariza-Marquez YV, Gomez-
796 Bello RM, Canadas-Garre M. Diabetes-Related Neurological Implications and
797 Pharmacogenomics. *Current pharmaceutical design*. 2018;24(15):1695-710.
- 798 10. Said G. Diabetic neuropathy. *Handbook of clinical neurology*. 2013;115:579-89.
- 799 11. Li L, Chen J, Wang J, Cai D. Prevalence and risk factors of diabetic peripheral
800 neuropathy in type 2 diabetes mellitus patients with overweight/obese in Guangdong
801 province, China. *Primary care diabetes*. 2015;9(3):191-5.
- 802 12. Pfannkuche A, Alhajjar A, Ming A, Walter I, Piehler C, Mertens PR. Prevalence and
803 risk factors of diabetic peripheral neuropathy in a diabetics cohort: Register initiative
804 “diabetes and nerves”. *Endocrine and Metabolic Science*. 2020;1(1):100053.
- 805 13. Bansal D, Gudala K, Muthyala H, Esam HP, Nayakallu R, Bhansali A. Prevalence
806 and risk factors of development of peripheral diabetic neuropathy in type 2 diabetes mellitus
807 in a tertiary care setting. *Journal of diabetes investigation*. 2014;5(6):714-21.
- 808 14. Katulanda P, Ranasinghe P, Jayawardena R, Constantine GR, Sheriff MHR,
809 Matthews DR. The prevalence, patterns and predictors of diabetic peripheral neuropathy in a
810 developing country. *Diabetology & Metabolic Syndrome*. 2012;4(1):21.

- 811 15. Shiferaw WS, Akalu TY, Work Y, Aynalem YA. Prevalence of diabetic peripheral
812 neuropathy in Africa: a systematic review and meta-analysis. *BMC endocrine disorders*.
813 2020;20(1):49.
- 814 16. Jacovides A, Bogoshi M, Distiller LA, Mahgoub EY, Omar MK, Tarek IA, et al. An
815 epidemiological study to assess the prevalence of diabetic peripheral neuropathic pain among
816 adults with diabetes attending private and institutional outpatient clinics in South Africa.
817 *Journal of International Medical Research*. 2014;42(4):1018-28.
- 818 17. Seid MA, Akalu Y, Gela YY, Belsti Y, Diress M, Fekadu SA, et al. Microvascular
819 complications and its predictors among type 2 diabetes mellitus patients at Dessie town
820 hospitals, Ethiopia. *Diabetology & Metabolic Syndrome*. 2021;13(1):1-8.
- 821 18. Bos M, Agyemang C. Prevalence and complications of diabetes mellitus in Northern
822 Africa, a systematic review. *BMC public health*. 2013;13(1):1-7.
- 823 19. Jember G, Melsew YA, Fisseha B, Sany K, Gelaw AY, Janakiraman B. Peripheral
824 Sensory Neuropathy and associated factors among adult diabetes mellitus patients in Bahr
825 Dar, Ethiopia. *Journal of diabetes and metabolic disorders*. 2017;16:16.
- 826 20. Jarso G, Ahmed A, Feleke Y. The prevalence, clinical features and management of
827 peripheral neuropathy among diabetic patients in Tikur Anbessa and St. Paul's Specialized
828 University Hospitals, Addis Ababa, Ethiopia. *Ethiopian medical journal*. 2011;49(4):299-
829 311.
- 830 21. Selvarajah D, Kar D, Khunti K, Davies M, Scott A, Walker J. Diabetic peripheral
831 neuropathy: Advances in diagnosis and strategies for screening and early intervention. *Lancet*
832 *Diabetes Endocrinol* [Internet]. 2019; 7 (12): 938–48.
- 833 22. (FMOH) FMOH. National Strategic Action Plan (Nsap) for Prevention & Control of
834 Non-Communicable Diseases in Ethiopia. 2016.
- 835 23. Smith BH, Hébert HL, Veluchamy A. Neuropathic pain in the community:
836 prevalence, impact, and risk factors. *Pain*. 2020;161 Suppl 1:S127-s37.
- 837 24. Marshall A, Alam U, Themistocleous A, Calcutt N, Marshall A. Novel and Emerging
838 Electrophysiological Biomarkers of Diabetic Neuropathy and Painful Diabetic Neuropathy.
839 *Clinical therapeutics*. 2021;43(9):1441-56.
- 840 25. Kent P, Cancelliere C, Boyle E, Cassidy JD, Kongsted A. A conceptual framework
841 for prognostic research. *BMC Med Res Methodol*. 2020;20(1):172.
- 842 26. Ambizas EM, Maniara B. Diabetic Peripheral Neuropathy How Can We Help Our
843 Patients? : JOBSON PUBLISHING LLC 100 AVE OF THE AMERICAS, NEW YORK, NY
844 10013-1678 USA; 2016. p. 8-14.
- 845 27. Yang Z, Zhang Y, Chen R, Huang Y, Ji L, Sun F, et al. Simple tests to screen for
846 diabetic peripheral neuropathy: *Cochrane Database Syst Rev*. 2018 Jul
847 30;2018(7):CD010975. doi: 10.1002/14651858.CD010975.pub2. eCollection 2018 Jul.
- 848 28. Lu Y, Xing P, Cai X, Luo D, Li R, Lloyd C, et al. Prevalence and Risk Factors for
849 Diabetic Peripheral Neuropathy in Type 2 Diabetic Patients From 14 Countries: Estimates of
850 the INTERPRET-DD Study. *Frontiers in Public Health*. 2020;8.
- 851 29. Moons KG, Royston P, Vergouwe Y, Grobbee DE, Altman DG. Prognosis and
852 prognostic research: what, why, and how? *Bmj*. 2009;338.
- 853 30. Chicharro-Luna E, Pomares-Gómez FJ, Ortega-Ávila AB, Coheña-Jiménez M, Gijon-
854 Nogueron G. Variability in the clinical diagnosis of diabetic peripheral neuropathy. *Primary*
855 *care diabetes*. 2020;14(1):53-60.
- 856 31. Coppini DV. Diabetic neuropathy: are we still barking up the wrong tree and is
857 change finally in sight? *Diabetologia*. 2020;63(9):1949-50.
- 858 32. Mendoza-Romo MA, Ramírez-Arriola MC, Velasco-Chávez JF, Nieva-de Jesús RN,
859 Rodríguez-Pérez CV, Valdez-Jiménez LA. [Sensitivity and specificity of a utility model of

- 860 the detection of diabetic neuropathy]. *Revista medica del Instituto Mexicano del Seguro*
861 *Social*. 2013;51(1):34-41.
- 862 33. Jambart S, Ammache Z, Haddad F, Younes A, Hassoun A, Abdalla K, et al.
863 Prevalence of painful diabetic peripheral neuropathy among patients with diabetes mellitus in
864 the Middle East region. *The Journal of international medical research*. 2011;39(2):366-77.
- 865 34. Chicharro-Luna E, Pomares-Gómez FJ. Predictive model to identify the risk of losing
866 protective sensibility of the foot in patients with diabetes mellitus. 2020;17(1):220-7.
- 867 35. Papanas N, Ziegler D. Polyneuropathy in impaired glucose tolerance: is postprandial
868 hyperglycemia the main culprit? A mini-review. *Gerontology*. 2013;59(3):193-8.
- 869 36. Xiao M-X, Lu C-H, Ta N, Wei H-C, Haryadi B, Wu H-T. Machine learning
870 prediction of future peripheral neuropathy in type 2 diabetics with percussion entropy and
871 body mass indices. *Biocybernetics and Biomedical Engineering*. 2021;41(3):1140-9.
- 872 37. Said G. Diabetic neuropathy. *Handbook of clinical neurology*. 2013;115:579-89.
- 873 38. Wolde HF, Atsedeweyen A, Jember A, Awoke T, Mequanent M, Tsegaye AT, et al.
874 Predictors of vascular complications among type 2 diabetes mellitus patients at University of
875 Gondar Referral Hospital: a retrospective follow-up study. *BMC Endocrine Disorders*.
876 2018;18(1):52.
- 877 39. Gebabo TF, Zewdie TH, Shagaro SS, Haile F. Determinants of peripheral neuropathy
878 among diabetic patients under follow-up in chronic care clinics of public hospitals at Gamo
879 and Gofa zones, southern Ethiopia. *PloS one*. 2021;16(2):e0246722.
- 880 40. Fan Y, Long E, Cai L, Cao Q, Wu X, Tong R. Machine Learning Approaches to
881 Predict Risks of Diabetic Complications and Poor Glycemic Control in Nonadherent Type 2
882 Diabetes. *Frontiers in pharmacology*. 2021;12:665951.
- 883 41. Wang N, Guo C, Han P, Li T. Glycated albumin indicates peripheral diabetic
884 neuropathy. *Acta diabetologica*. 2016;53(6):973-9.
- 885 42. Yamazaki D, Hitomi H, Nishiyama A. Hypertension with diabetes mellitus
886 complications. *Hypertension Research*. 2018;41(3):147-56.
- 887 43. Cai Z, Yang Y, Zhang J. A systematic review and meta-analysis of the serum lipid
888 profile in prediction of diabetic neuropathy. *Sci Rep*. 2021;11(1):499.
- 889 44. Tabatabaei-Malazy O, Mohajeri-Tehrani M, Madani S, Heshmat R, Larijani B. The
890 prevalence of diabetic peripheral neuropathy and related factors. *Iranian journal of public*
891 *health*. 2011;40(3):55.
- 892 45. Wu B, Niu Z, Hu F. Study on Risk Factors of Peripheral Neuropathy in Type 2
893 Diabetes Mellitus and Establishment of Prediction Model. *Diabetes Metab J*. 2021;45(4):526-
894 38.
- 895 46. Abougalambou SS, Abougalambou AS. Explorative study on diabetes neuropathy
896 among type II diabetic patients in Universiti Sains Malaysia Hospital. *Diabetes & metabolic*
897 *syndrome*. 2012;6(3):167-72.
- 898 47. Nalluri L, Mannam M, Vemireddy N, Akula N, Pothuraju M, Pinnika D, et al.
899 Assessment of drug utilization pattern and risk factors for the development of diabetic
900 neuropathy among type 2 diabetic patients in a south Indian hospital: A cross-sectional
901 observational study. *Journal of Applied Pharmaceutical Science*. 2019;9(12):069-77.
- 902 48. Feldman EL, Callaghan BC, Pop-Busui R, Zochodne DW, Wright DE, Bennett DL, et
903 al. Diabetic neuropathy. *Nature reviews Disease primers*. 2019;5(1):1-18.
- 904 49. Steyerberg EW, Moons KG, van der Windt DA, Hayden JA, Perel P, Schroter S, et al.
905 Prognosis Research Strategy (PROGRESS) 3: prognostic model research. *PLoS medicine*.
906 2013;10(2):e1001381.
- 907 50. Tadesse DB, Gebrewahd GT, Hailay A, Aberhe W, Mebrahtom G, Zereabruk K, et al.
908 Diabetic peripheral neuropathy in Ethiopia: a systematic review and meta-analysis. *Journal of*
909 *Diabetes Research*. 2021;2021.

- 910 51. Gill G, Mbanya J-C, Ramaiya K, Tesfaye S. A sub-Saharan African perspective of
911 diabetes. *Diabetologia*. 2009;52(1):8-16.
- 912 52. Assessment G. 6. Glycemic Targets: Standards of Medical Care in Diabetes—2022.
913 *Diabetes Care*. 2022;45:S83.
- 914 53. Carroll MD, Kit BK, Lacher DA. Total and high-density lipoprotein cholesterol in
915 adults; national health and nutrition examination survey, 2009-2010. 2012.
- 916 54. Bain BJ. *Blood cells: a practical guide*: John Wiley & Sons; 2021.
- 917 55. Kent S, Fusco F, Gray A, Jebb SA, Cairns BJ, Mihaylova B. Body mass index and
918 healthcare costs: a systematic literature review of individual participant data studies. *Obesity*
919 *Reviews*. 2017;18(8):869-79.
- 920 56. Balachandran VP, Gonen M, Smith JJ, DeMatteo RP. Nomograms in oncology: more
921 than meets the eye. *The Lancet Oncology*. 2015;16(4):e173-80.
- 922 57. Ge X, Pan SM, Zeng F, Tang ZH, Wang YW. A simple Chinese risk score model for
923 screening cardiovascular autonomic neuropathy. *PloS one*. 2014;9(3):e89623.
- 924 58. Collins GS, Reitsma JB, Altman DG, Moons KG. Transparent reporting of a
925 multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD
926 statement. *Journal of British Surgery*. 2015;102(3):148-58.
- 927 59. Vickers AJ, van Calster B, Steyerberg EW. A simple, step-by-step guide to
928 interpreting decision curve analysis. *Diagnostic and prognostic research*. 2019;3:18.
- 929 60. Jensen TS, Karlsson P, Gylfadottir SS, Andersen ST, Bennett DL, Tankisi H, et al.
930 Painful and non-painful diabetic neuropathy, diagnostic challenges and implications for
931 future management. *Brain*. 2021;144(6):1632-45.
- 932 61. Malik RA, Andag-Silva A, Dejthevaporn C, Hakim M, Koh JS, Pinzon R, et al.
933 Diagnosing peripheral neuropathy in South-East Asia: a focus on diabetic neuropathy.
934 *Journal of Diabetes Investigation*. 2020;11(5):1097-103.
- 935 62. Ponirakis G, Elhadd T, Chinnaiyan S, Dabbous Z, Siddiqui M, Al-muhannadi H, et al.
936 Prevalence and management of diabetic neuropathy in secondary care in Qatar.
937 *Diabetes/Metabolism Research and Reviews*. 2020;36(4):e3286.
- 938 63. Heckmann T, Gegg K, Gegg A, Becht M. Sample size matters: investigating the
939 effect of sample size on a logistic regression susceptibility model for debris flows. *Natural*
940 *Hazards and Earth System Sciences*. 2014;14(2):259-78.
- 941 64. Bando H. Significant Neurological Study for Lifestyle Related Diseases Worldwide
942 From Now. *Journal of Health Care and Research*. 2020;1(2):50-4.
- 943 65. Fasil A, Biadgo B, Abebe M. Glycemic control and diabetes complications among
944 diabetes mellitus patients attending at University of Gondar Hospital, Northwest Ethiopia.
945 *Diabetes, metabolic syndrome and obesity: targets and therapy*. 2019;12:75.
- 946 66. YimamAhmed M, Ejigu SH, Zeleke AZ, Hassen MY. Glycemic control, diabetes
947 complications and their determinants among ambulatory diabetes mellitus patients in
948 southwest ethiopia: A prospective cross-sectional study. *Diabetes, Metabolic Syndrome and*
949 *Obesity: Targets and Therapy*. 2020;13:1089.
- 950 67. Huang L, Shen X, Huang L, Yan S, Wu P. Identification of independent risk factors
951 for diabetic neuropathy progression in patients with type 2 diabetes mellitus. *Journal of*
952 *International Medical Research*. 2021;49(9):03000605211044366.
- 953 68. Šimundić A-M. Measures of diagnostic accuracy: basic definitions. *Ejifcc*.
954 2009;19(4):203.
- 955 69. Ge X, Pan S-M, Zeng F, Tang Z-H, Wang Y-W. A simple Chinese risk score model
956 for screening cardiovascular autonomic neuropathy. *PloS one*. 2014;9(3):e89623.
- 957 70. Liao L-N, Li T-C, Li C-I, Liu C-S, Lin W-Y, Lin C-H, et al. Genetic risk score for
958 risk prediction of diabetic nephropathy in Han Chinese type 2 diabetes patients. *Scientific*
959 *reports*. 2019;9(1):1-9.

- 960 71. Maeda-Gutiérrez V, Galván-Tejada CE, Cruz M, Valladares-Salgado A, Galván-
961 Tejada JI, Gamboa-Rosales H, et al., editors. Distal symmetric polyneuropathy identification
962 in type 2 diabetes subjects: A random forest approach. *Healthcare*; 2021: MDPI.
- 963 72. Wu B, Niu Z, Hu F. Study on Risk Factors of Peripheral Neuropathy in Type 2
964 Diabetes Mellitus and Establishment of Prediction Model. *Diabetes & metabolism journal*.
965 2021;45(4):526-38.
- 966 73. Shin DY, Lee B, Yoo WS, Park JW, Hyun JK. Prediction of Diabetic Sensorimotor
967 Polyneuropathy Using Machine Learning Techniques. *Journal of Clinical Medicine*.
968 2021;10(19):4576.
- 969 74. Muschelli J. ROC and AUC with a binary predictor: a potentially misleading metric.
970 *Journal of classification*. 2020;37(3):696-708.
- 971 75. Dagliati A, Marini S, Sacchi L, Cogni G, Teliti M, Tibollo V, et al. Machine learning
972 methods to predict diabetes complications. *Journal of diabetes science and technology*.
973 2018;12(2):295-302.
- 974 76. Marshall A, Alam U, Themistocleous A, Calcutt N, Marshall A. Novel and emerging
975 electrophysiological biomarkers of diabetic neuropathy and painful diabetic neuropathy.
976 *Clinical therapeutics*. 2021;43(9):1441-56.
- 977 77. Petropoulos IN, Ponirakis G, Khan A, Almuhammad H, Gad H, Malik RA.
978 Diagnosing diabetic neuropathy: something old, something new. *Diabetes & metabolism*
979 *journal*. 2018;42(4):255.

980

981

medRxiv preprint doi: <https://doi.org/10.1101/2022.10.10.22280924>; this version posted October 11, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](#).




Figure 1:-Flowchart of participant selection for the development of nomogram for prediction of diabetic neuropathy among DM patients in selected referral hospitals, Amhara regional state, North West Ethiopia, 2005-2021.






Figure 2; Pie chart for the proportion of diabetic neuropathy among diabetes mellitus patients North West, Ethiopia, 2005-2021.



medRxiv preprint doi: <https://doi.org/10.1101/2022.10.10.22280924>; this version posted October 11, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

(A)

(B)

Figure 3: The performance of the model using original beta coefficients A) AUC B) calibration plot, for prediction of diabetic neuropathy among DM patients North West Ethiopia, 2005-2021.






Figure 4:- Nomogram for develop and validate risk prediction model for diabetic neuropathy among diabetes mellitus patients, northwest Ethiopia, 2005-2021.




(A)



(B)

medRxiv preprint doi: <https://doi.org/10.1101/2022.10.10.22280924>; this version posted October 11, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).


Figure 5: Performance of model using nomogram A) AUC B) Calibration plot, prediction for the risk of diabetic neuropathy among DM patients North West Ethiopia 2005-2021.




medRxiv preprint doi: <https://doi.org/10.1101/2022.10.10.22280924>; this version posted October 14, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Figure 6:-Classification and regression decision tree for prediction of diabetic neuropathy among diabetes mellitus patients North West Ethiopia 2005-2021

medRxiv preprint doi: <https://doi.org/10.1101/2022.10.10.22280924>; this version posted October 11, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).



(A)



(B)

Figure 7:-The Performance of the model using decision tree A) AUC B) calibration plot to prediction of the risk for diabetic neuropathy among DM patients North West Ethiopia 2022.

medRxiv preprint doi: <https://doi.org/10.1101/2022.10.10.22280924>; this version posted October 11, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).




Figure 8: The performance of the model using nomogram after bootstrapping A) Area under the curve (AUC) B) calibration plot, for the probability of the risk of diabetic neuropathy among DM patients North West Ethiopia, 2005-2021.

medRxiv preprint doi: <https://doi.org/10.1101/2022.10.10.22280924>; this version posted October 11, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).




Figure 10: Comparison of nomogram and decision tree for prediction of diabetic neuropathy among DM patients North West Ethiopia 2005-2021.

medRxiv preprint doi: <https://doi.org/10.1101/2022.10.10.22280924>; this version posted October 11, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](#).




Figure 11:-Decision curve plot A) Nomogram B) Decision tree ,showing the net benefit of the developed model for carrying out a certain intervention measure in DM patients at risk of diabetic neuropathy Northwest Ethiopia, 2005-2021

Diabetic Neuropathy Risk Prediction Calculator

Glycemic Control <130 mg/dl 0

Other comorbidities Yes 7

Alcohol Drinking Yes 6.4

Type of treatment Insulin 0

Hypertension No 0

Physical Activity Yes 0

WBC >=11000 cells/mcl 7.8

RBC >=4 million cells/mcl 0

Calculate Cumulative Score 21.2

Clear

medRxiv preprint doi: <https://doi.org/10.1101/2022.10.10.22280924>; this version posted October 11, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Figure 12:-Mobile based application outputs for predicting risk of diabetic neuropathy among DM patients Northwest Ethiopia 2005-2021.

medRxiv preprint doi: <https://doi.org/10.1101/2022.10.10.22280924>; this version posted October 11, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).




Figure 9:-The performance of the model using classification and regression decision tree after bootstrapping A) AUC B) Calibration plot to predict diabetic neuropathy among DM patients northwest Ethiopia 2022.